Women’s interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid
暂无分享,去创建一个
Sarah M. Greene | Angela Fagerlin | Jennifer B. McClure | Daniel F. Hayes | Brian J. Zikmund-Fisher | Sarah Greene | Sharon Hensley Alford | Vijayan Nair | Peter A. Ubel | P. Ubel | B. Zikmund‐Fisher | J. McClure | Cheryl J Wiese | V. Nair | Dylan M. Smith | A. Fagerlin | D. Hayes | Amanda J. Dillard | R. Pitsch | Sarah M Greene | S. Alford | Rosemarie Pitsch | Cheryl Wiese
[1] J. Cacioppo,et al. The need for cognition. , 1982 .
[2] P. Ubel,et al. Measuring Numeracy without a Math Test: Development of the Subjective Numeracy Scale , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[3] Steven L. Neuberg,et al. Personal Need for Structure: Individual Differences in the Desire for Simple Structure , 1993 .
[4] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[5] A. O'Connor. Validation of a Decisional Conflict Scale , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.
[6] E. Port,et al. Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary Prevention , 2001, Annals of Surgical Oncology.
[7] M. Regan,et al. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] O. Olopade,et al. “Why take it if you don’t have anything?” breast cancer risk perceptions and prevention choices at a public hospital , 2006, Journal of General Internal Medicine.
[9] D. Paterniti,et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction , 2005, Cancer.
[10] Dawn Stacey,et al. Development and evaluation of a breast cancer prevention decision aid for higher‐risk women , 2003, Health expectations : an international journal of public participation in health care and health policy.
[11] S. Narod,et al. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation , 2005, Familial Cancer.
[12] S. Corson. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes , 2006 .
[13] Erika A. Waters,et al. Prevalence of Tamoxifen Use for Breast Cancer Chemoprevention Among U.S. Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[14] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[15] M. Morrow. Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial , 2007 .
[16] R. Donovan,et al. The word ‘cancer’: reframing the context to reduce anxiety arousal , 2003, Australian and New Zealand journal of public health.
[17] Sarah M. Greene,et al. Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid , 2010, Breast Cancer Research and Treatment.
[18] P. Butow,et al. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. Redelmeier,et al. Medical decision making in situations that offer multiple alternatives. , 1995, JAMA.
[20] P. Ubel,et al. Validation of the Subjective Numeracy Scale: Effects of Low Numeracy on Comprehension of Risk Communications and Utility Elicitations , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.